UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 11.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,621,886 shares of the biopharmaceutical company's stock after selling 350,315 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.45% of Royalty Pharma worth $66,884,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RPRX. Worldquant Millennium Advisors LLC raised its position in shares of Royalty Pharma by 49.4% in the 4th quarter. Worldquant Millennium Advisors LLC now owns 610,173 shares of the biopharmaceutical company's stock worth $15,566,000 after purchasing an additional 201,648 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Royalty Pharma by 21.1% in the 4th quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock worth $93,703,000 after acquiring an additional 640,000 shares during the last quarter. State of Wyoming boosted its stake in Royalty Pharma by 129.5% during the 4th quarter. State of Wyoming now owns 15,096 shares of the biopharmaceutical company's stock valued at $385,000 after purchasing an additional 8,518 shares during the last quarter. Sherbrooke Park Advisers LLC lifted its holdings in shares of Royalty Pharma by 1.1% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after purchasing an additional 380 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new stake in Royalty Pharma in the 4th quarter worth about $506,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Trading Up 0.9%

RPRX stock traded up $0.30 during trading on Friday, hitting $32.94. The company had a trading volume of 836,879 shares, compared to its average volume of 3,459,691. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.32. The company has a 50 day simple moving average of $32.32 and a 200-day simple moving average of $30.34. The firm has a market capitalization of $18.52 billion, a P/E ratio of 22.75, a PEG ratio of 2.31 and a beta of 0.49. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The firm had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. As a group, research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.67%. The ex-dividend date is Friday, May 16th. Royalty Pharma's payout ratio is 47.57%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Tuesday, May 20th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Morgan Stanley began coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They issued an "overweight" rating and a $51.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.